Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based Precision Rehabilitation
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Apr 18, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how wearable technology can help assess and treat people with mild traumatic brain injuries (mTBI), including concussions. The researchers believe that traditional methods may not catch all the subtle issues patients face after an injury. By using wearable sensors, they aim to provide real-time feedback to participants during physical therapy. This feedback will help improve movement quality while performing exercises related to balance and walking. The study will compare this new approach with a standard rehabilitation program to see which is more effective.
To join the study, participants must be between 18 and 50 years old, have a diagnosed mTBI, and still be experiencing symptoms. They need to be able to stand without help for at least 10 minutes and must not have any other conditions that could affect balance or vision. Participants can expect to receive physical therapy aimed at improving their balance, with the added benefit of personalized feedback from the wearable technology. This research could lead to better treatment options for mTBI and help healthcare providers create effective rehabilitation guidelines in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * For all Aims, participants may be either civilians, active duty military, or Veterans, and must:
- • 1. have a diagnosis of mTBI based on VA/DoD criteria
- • 2. be between 18-60 years old,
- • 3. be able to stand unassisted for 10 minutes at a time
- • 4. be outside of the acute stage (\> 2 weeks post-concussion) but within 6 months of their most recent mTBI and still reporting symptoms
- • 5. have at least some measurable deficit in Vestibular/Ocular categories based on Concussion Profile Screen
- • 6. have sufficient vision (corrected or uncorrected) for unassisted reading and performance of everyday personal tasks and independent community ambulation
- • 7. have adequate hearing (without amplification) adequate for engaging in close-range personal or telephone conversation.
- Exclusion Criteria:
- * Participants must not:
- • 1. have had or currently have any other injury, medical, or neurological illness that could potentially explain balance or vision deficits (e.g., CNS disease, stroke, epilepsy, greater than mild TBI, Meniere's, bilateral vestibular loss, recent lower extremity or spine orthopedic injury requiring a profile) this includes unresolved symptoms from previous concussions
- • 2. meet criteria for moderate to severe substance-use disorder within the past month, as defined by DSM-V
- • 3. display behavior that would significantly interfere with the validity of data collection or safety during the study
- • 4. be in significant pain during the evaluation (\> 7/10 by patient subjective report)
- • 5. be a pregnant female (balance considerations)
- • 6. been hospitalized for any brain injuries (separate from the emergency department)
- • 7. have significant joint pain or recent musculoskeletal injury that limits walking or mobility
- • 8. have had any major surgeries in the past year or amputation
- • 9. use an assistive device
- • 10. unable to stand barefoot
- • 11. currently receiving rehabilitation services for their mTBI or injuries related to their concussion (if rehabilitation has been completed more than 1 month ago participants may still be included).
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Salt Lake City, Utah, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Laurie A King, PhD, DPT
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported